The tumors from patients responding to ICI (responding tumors) were found to have significantly elevated CD8+ and CD3+ counts at the invasive tumor margin (CD8+, P = 0.016; CD3+, P = 0.001) (Fig. 1b,d; Supplementary Fig. 1a,c). This evidence concerns the gene CD8A and neoplasm.